AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novel Coronavirus Treatment

1,018.665

-7.367-0.72%

Number of Gainers:7

Number of Losers:11

Number of Flat:14

PE:- -

High:1,025.900

Open:1,025.733

Low:1,016.660

Close:1,026.032

Loading ...

This LARK Distilling Insider Increased Their Holding By 256% Last Year

Simply Wall St.

BUZZ-Citi predicts click & collect fees to aid cost recovery for Australian supermarkets

ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says

MT Newswires Live

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs -- Update

5 of the best ASX 200 shares to buy after the market selloff

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

Own CSL shares? You're getting a dividend paycheque today

BUZZ-Australia's CSL hits nearly 18-month low on tariff concerns

BRIEF-Australia's ACCC Says Woolworths' Acquisition Of Beak & Johnston Not Opposed

BRIEF-IDT Australia Secures Manufacturing Contract With Nacuity Pharmaceuticals For RP Treatment

BUZZ-IDT Australia gains on $1.9 million contract

Pharmaceuticals to be hit by ‘major’ Trump tariff, CSL slumps 5pc

The Australian Financial Review

Woolworths Group's Beak & Johnston Acquisition Cleared by ACCC

MT Newswires Live

Is it time to be fearful or greedy with ASX shares?

ResMed CFO Sells Shares

MT Newswires Live

IDT Australia Ltd - Five-Year Contract With Initial a$3.2M Work Expected to Complete by FY2026

THOMSON REUTERS

IDT Australia - Secures Manufacturing Contract With Nacuity Pharmaceuticals for Rp Treatment

THOMSON REUTERS

Australia's Accc - Woolworths' Acquisition of Beak & Johnston Not Opposed

THOMSON REUTERS

Australia's Accc - Unlikely Acquisition Would Have Substantial Anti-Competitive Effect

THOMSON REUTERS

Ansell Loses Bull Despite Tariff Mitigation Plans -- Market Talk

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7501/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"Novel Coronavirus Treatment","latestPrice":1018.66534,"timestamp":1745301599918,"preClose":1026.0322,"halted":0,"volume":32454052,"delay":0,"changeRate":-0.00718,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-7.366882,"latestTime":"04-22 16:00:00 AEST","open":1025.7329,"high":1025.9,"low":1016.6596,"amount":449354068,"amplitude":0.009006,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745280000000,1745301600000]],"turnoverRate":0.002358,"increases":6,"decrements":13,"flats":13,"marketCap":256166897347.25,"floatMarketCap":211264566183.58594},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":1025.9,"amplitude":0.009006,"preClose":1026.0322,"low":1016.6596,"latestPrice":1018.66534,"volume":32454052,"delay":0,"open":1025.7329,"prevYearClose":1117.913,"prevWeekClose":1026.032,"prevMonthClose":1021.93,"prevQuarterClose":1021.93,"fiveDayClose":1011.058,"twentyDayClose":1032.105,"sixtyDayClose":1090.626,"secType":"PLATE","market":"AU","turnoverRate":0.002358,"marketCap":256166897347.25,"floatMarketCap":211264566183.58594,"timestamp":1745301599918,"nameCN":"Novel Coronavirus Treatment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":7,"down":11,"flat":14},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526372307","title":"This LARK Distilling Insider Increased Their Holding By 256% Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2526372307","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526372307?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:14","pubTimestamp":1744229657,"startTime":"0","endTime":"0","summary":"Looking at LARK Distilling Co. Ltd.'s ( ASX:LRK ) insider transactions over the last year, we can see that insiders...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/5112000-choice1-main-header/1585186807175","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5112000-choice1-main-header/1585186807175"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/food-beverage-tobacco/asx-lrk/lark-distilling-shares/news/this-lark-distilling-insider-increased-their-holding-by-256-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7097","LARK","LRK.AU","BK7501","BK4211"],"gpt_icon":0},{"id":"2526348535","title":"BUZZ-Citi predicts click & collect fees to aid cost recovery for Australian supermarkets","url":"https://stock-news.laohu8.com/highlight/detail?id=2526348535","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526348535?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:03","pubTimestamp":1744229013,"startTime":"0","endTime":"0","summary":"BUZZ-Citi predicts click & collect fees to aid cost recovery for Australian supermarkets** Citi analysts project that the introduction of click and collect (C&C) fees would partly recover costs for Australian supermarkets ** Brokerage says C&C fees would also help incentivise more in-store purchases, where profit margins are the highest** We believe a charge of ~A$5 for regular C&C is a suitable starting point for Woolworths WOW.AX and Coles COL.AX, recovering ~25% of the estimated direct labour costs - Citi** Brokerage says Coles remains its preferred pick in the Australian supermarkets sector, maintains \"buy\" rating on stock** Aussie consumer staple index .AXSJ up 1.4% YTD, while Aussie consumer discretionary index .AXDJ down 7.8% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nL3N3QN24E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7040","BK7511","BK7082","BK7501","COL.AU","WOW.AU"],"gpt_icon":0},{"id":"2526312885","title":"ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2526312885","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526312885?lang=en_us&edition=fundamental","pubTime":"2025-04-10 02:45","pubTimestamp":1744224348,"startTime":"0","endTime":"0","summary":"ResMed's  fiscal Q3 is likely to meet consensus estimates, but the company is facing potential supply chain disruption risks due to US tariffs, UBS said in a Wednesday note.UBS estimates fiscal Q3 revenue of $1.28 billion and a core gross margin of roughly 60%, both in line with Visible Alpha consensus. It also estimates core earnings of $2.32 per share, which is slightly below the consensus, according to the note.The brokerage said it forecasts a roughly 1% negative near-term impact on EPS due to tariffs and is \"mindful\" of freight costs and their potential impact on the company's gross margins.ResMed will report its fiscal Q3 financial results on April 23.UBS said ResMed is working to lift gross margins above 60%, and it sees \"core gross margin back at that level in FY25, which is more optimistic than the consensus expectation of FY26.\"UBS maintained its buy rating on the stock and 12-month price target of $290 per share.Price: 214.92, Change: +10.38, Percent Change: +5.07","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","RMD.AU","BK7501","BK4567","RMD","BK4504","BK7007","LU0170899867.USD","LU2008162690.USD","BK4082","BK4588","LU2177674079.SGD","BK4548"],"gpt_icon":0},{"id":"2526963233","title":"Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2526963233","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526963233?lang=en_us&edition=fundamental","pubTime":"2025-04-09 23:03","pubTimestamp":1744210980,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks sank lower Wednesday after President Trump doubled down on his promise to slap tariffs on a long-exempt industry, causing market turmoil globally.The Dow Jones U.S. Pharmaceuticals Index slipped 3.7% to 768.75 Wednesday morning, at one point hitting a 52-week low of 766.61. AbbVie shares fell 5.9% to $165.34, while Eli Lilly, Merck and Pfizer all declined about 3%.In European morning trade, the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--dropped 3.1% Wednesday, also touching a year low earlier in the session.Switzerland's Roche and Novartis, the U.K.'s AstraZeneca, Denmark's Novo Nordisk and France's Sanofi were all down more than 5% in morning trade. Japan's Daiichi Sankyo and Takeda Pharmaceutical retreated 6% and 4.7%, respectively, while Australia's CSL shed 5%.The pharma sector had been spared last week from Trump's sweeping tariff plan, which kicked in Wednesday, and drug companies have been exempt","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK","LU0158827948.USD","03165","LU1496350171.SGD","IE00BZ1G4Q59.USD","SG9999002224.SGD","NVO","ABBV","LU0070302665.USD","DSNKY","LU2237443382.USD","IE00B19Z3581.USD","IE00B3PB1722.GBP","BK7511","LU1983299246.USD","LU1066051811.HKD","LU2347655156.SGD","LU1003077747.HKD","LU0385154629.USD","LU0029864427.USD","IE00BJLML261.HKD","LU0943347566.SGD","BK7501","LU0708995401.HKD","LU0553294199.USD","LU0061475181.USD","LU1804176565.USD","SG9999001440.SGD","CSL.AU","LU2462157665.USD","LU0109391861.USD","SNY","LU2602419157.SGD","LU0208291251.USD","LLY","LU1720051108.HKD","LU1366192091.USD","SG9999015945.SGD","LU0265550359.USD","LU2552382132.HKD","RHHBY","AZN","LU0882574139.USD","LU1829250122.USD","TAK","NVS","LU2129689605.HKD","PFE","IE00BVYPNV92.GBP","LU1035775433.USD"],"gpt_icon":1},{"id":"2526933271","title":"5 of the best ASX 200 shares to buy after the market selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=2526933271","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526933271?lang=en_us&edition=fundamental","pubTime":"2025-04-09 16:23","pubTimestamp":1744186987,"startTime":"0","endTime":"0","summary":"If you have room in your portfolio for some new ASX 200 shares after the market selloff, then read on!","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/09/5-of-the-best-asx-200-shares-to-buy-after-the-market-selloff/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2471134796.USD","WOW.AU","IE0004086264.USD","LU2237443978.SGD","LU0742534661.SGD","LU1868836757.USD","LIF","LU2750360997.AUD","BK4552","LU2471134879.HKD","XAO.AU","NXT.AU","BK7043","BK4023","IE00BSNM7G36.USD","BK7016","BK7507","BK4533","LU2237443549.SGD","LU1868836591.USD","BK4613","360.AU","IE00B19Z3B42.SGD","LU2471134523.USD","BK4516","BK7095","BK7501","BK4585","WTC.AU","IE0034235188.USD","LU2237438978.USD","LU1868837136.USD","BHP.AU","LU0096364046.USD","LU2237443465.HKD","BK7511","LU1668664300.SGD","LU1868836914.USD","LU2471134952.CNY","BK4588","IE00B19Z3581.USD","LU2237443622.USD","LU0048573561.USD","BK4127","LU1791807156.HKD","XKO.AU","IE0004091025.USD","XJO.AU","IE00BFXG1179.USD","LU0061475181.USD"],"gpt_icon":0},{"id":"2526381051","title":"CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526381051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526381051?lang=en_us&edition=fundamental","pubTime":"2025-04-09 15:01","pubTimestamp":1744182060,"startTime":"0","endTime":"0","summary":"0701 GMT - Australia-based biotech company CSL, which collects plasma in the U.S. and manufactures many plasma-based products at plants in Europe, would likely need to raise prices by between 4% to 5.1% to offset Trump's planned tariffs on pharmaceuticals, say Jefferies analysts. While it isn't clear exactly how the Trump pharmaceutical tariffs will work, the good news for CSL is that over time it may be able to move plasma product manufacturing from high tariff locations in Europe to lower tariff areas like Australia, say David Stanton and Vanessa Thomson. This will put it in a slightly better position than its major European competitors. But in general, \"plasma companies may see difficulties transferring complex, expensive operations at plants that can take years to build,\" they add. CSL shares ended 5% lower. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL","CSL.AU","BK7501","BK7067","BK7508","LU0728928796.USD","SG9999004303.SGD","LU1169590202.USD","SGXZ23171101.USD","BK7511","BK4086","LU1169589451.USD"],"gpt_icon":0},{"id":"2526406303","title":"Own CSL shares? You're getting a dividend paycheque today","url":"https://stock-news.laohu8.com/highlight/detail?id=2526406303","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526406303?lang=en_us&edition=fundamental","pubTime":"2025-04-09 11:29","pubTimestamp":1744169340,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) is once again selling off this Wednesday, losing the momentum we saw yesterday, and dropping substantially so far this session. At the time of writing, the ASX 200 has","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/09/own-csl-shares-youre-getting-a-dividend-paycheque-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7511","LU1169590202.USD","LU0728928796.USD","BK7508","BK7501","XJO.AU","CSL.AU","BK4086","CSL","SG9999004303.SGD","SGXZ23171101.USD","BK7067","LU1169589451.USD"],"gpt_icon":0},{"id":"2526176872","title":"BUZZ-Australia's CSL hits nearly 18-month low on tariff concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2526176872","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526176872?lang=en_us&edition=fundamental","pubTime":"2025-04-09 10:08","pubTimestamp":1744164491,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL hits nearly 18-month low on tariff concerns** Shares of CSL CSL.AX fall as much as 6.7% to A$229.2, their lowest level since Oct. 30, 2023. ** Shares trim some losses to last trade 4.6% lower. ** Biotech giant bears the brunt of U.S. plans to announce a \"major\" tariff on pharmaceutical imports** U.S. President Donald Trump said the tariff will incentivize drug companies to move their operations to the U.S.** Health stocks .AXHJ are down 2.3%, while the broader ASX 200 index .AXJO falls 1.2%** CSL has lost 12.7% YTD, including the day's move  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nL3N3QN05R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","CSL.AU","BK7067","BK7501"],"gpt_icon":0},{"id":"2526879906","title":"BRIEF-Australia's ACCC Says Woolworths' Acquisition Of Beak & Johnston Not Opposed","url":"https://stock-news.laohu8.com/highlight/detail?id=2526879906","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526879906?lang=en_us&edition=fundamental","pubTime":"2025-04-09 09:29","pubTimestamp":1744162144,"startTime":"0","endTime":"0","summary":"BRIEF-Australia's ACCC Says Woolworths' Acquisition Of Beak & Johnston Not OpposedApril 9  - Australia's ACCC:WOOLWORTHS' ACQUISITION OF BEAK & JOHNSTON NOT OPPOSEDUNLIKELY ACQUISITION WOULD HAVE SUBSTANTIAL ANTI-COMPETITIVE EFFECTFurther company coverage: WOW.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM244:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","WOW.AU","BK7511","BK7040"],"gpt_icon":0},{"id":"2526879624","title":"BRIEF-IDT Australia Secures Manufacturing Contract With Nacuity Pharmaceuticals For RP Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526879624","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526879624?lang=en_us&edition=fundamental","pubTime":"2025-04-09 09:28","pubTimestamp":1744162114,"startTime":"0","endTime":"0","summary":"BRIEF-IDT Australia Secures Manufacturing Contract With Nacuity Pharmaceuticals For RP TreatmentApril 9  - IDT Australia Ltd IDT.AX:SECURES MANUFACTURING CONTRACT WITH NACUITY PHARMACEUTICALS FOR RP TREATMENTFIVE-YEAR CONTRACT WITH INITIAL A$3.2M WORK EXPECTED TO COMPLETE BY FY2026Further company coverage: IDT.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM28L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDT.AU","BK7501","BK7096"],"gpt_icon":0},{"id":"2526487961","title":"BUZZ-IDT Australia gains on $1.9 million contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2526487961","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526487961?lang=en_us&edition=fundamental","pubTime":"2025-04-09 09:26","pubTimestamp":1744162014,"startTime":"0","endTime":"0","summary":"BUZZ-IDT Australia gains on $1.9 million contract** Shares of IDT Australia RIC rise 8.9% to A$0.098; marks biggest intraday percentage gain since January 28** The pharma manufacturer secures manufacturing contract with Nacuity Pharmaceuticals Pty for NPI-001, an investigational treatment for retinitis pigmentosa** Five-year contract with initial A$3.2 million  work expected to complete by FY2026, adds co** Stock down 18.2% this year, as of last close","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nL3N3QN042:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7501","IDT.AU"],"gpt_icon":0},{"id":"2526287928","title":"Pharmaceuticals to be hit by ‘major’ Trump tariff, CSL slumps 5pc","url":"https://stock-news.laohu8.com/highlight/detail?id=2526287928","media":"The Australian Financial Review","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526287928?lang=en_us&edition=fundamental","pubTime":"2025-04-09 09:08","pubTimestamp":1744160880,"startTime":"0","endTime":"0","summary":"US President Donald Trump says he is preparing to announce a “major” tariff on pharmaceuticals in an expansion of his damaging trade war that would hit $1.6 billion in annual Australian exports.“We are going to tariff our pharmaceuticals and once we do that they’re going to come rushing back into our country because we’re the big market,” he said in a televised address to the National Republican Congressional Committee on Tuesday .Loading...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.afr.com/companies/healthcare-and-fitness/pharmaceuticals-to-be-hit-by-major-trump-tariff-csl-slumps-5pc-20250409-p5lqeo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["SG9999004303.SGD","SGXZ23171101.USD","CSL.AU","BK7508","BK7501","BK4086","LU1169590202.USD","LU1169589451.USD","BK7511","CSL","LU0728928796.USD","BK7067"],"gpt_icon":0},{"id":"2526875033","title":"Woolworths Group's Beak & Johnston Acquisition Cleared by ACCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2526875033","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526875033?lang=en_us&edition=fundamental","pubTime":"2025-04-09 09:07","pubTimestamp":1744160876,"startTime":"0","endTime":"0","summary":"The Australian Competition and Consumer Commission (ACCC) will not oppose Woolworths Group's (ASX:WOW) proposed acquisition of Beak & Johnston Holdings, according to a Wednesday statement by the regul","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7511","WOW.AU","BK7040","BK7501"],"gpt_icon":0},{"id":"2526498873","title":"Is it time to be fearful or greedy with ASX shares?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526498873","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526498873?lang=en_us&edition=fundamental","pubTime":"2025-04-09 08:24","pubTimestamp":1744158256,"startTime":"0","endTime":"0","summary":"The ASX share market has seen plenty of declines in the last few weeks, and the global stock market is experiencing an even rougher time. The S&P 500 Index  has fallen close to 20% since 19 February 2025.  Investors are responding to the news that the US has applied tariffs on almost all countries and virtually all of the products from those countries. Trump has decided to add additional tariffs on Chinese goods after China responded with additional tariffs to the initial US tariff announcement. This has created uncertainty in investors' minds about what will happen and how things could play out next. Plenty of investors have been pushing the sell button amid this bout of fear. Is this the time to be fearful or greedy with ASX shares?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/09/is-it-time-to-be-fearful-or-greedy-with-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","ANN.AU","BK7126"],"gpt_icon":0},{"id":"2526182795","title":"ResMed CFO Sells Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2526182795","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526182795?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:48","pubTimestamp":1744156090,"startTime":"0","endTime":"0","summary":"ResMed's  Chief Financial Officer Brett Sandercock sold 1,000 common shares on the New York Stock Exchange for $215,580 in total, according to a Wednesday filing with the Australian bourse.Following the sale of shares, Sandercock owns about 146.9 million shares in the company, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","BK4504","BK4585","BK4082","RMD.AU","LU2177674079.SGD","RMD","BK4567","LU2008162690.USD","BK4588","XAO.AU","XKO.AU","LU0170899867.USD","BK7007","BK4548","BK7501"],"gpt_icon":0},{"id":"2526220138","title":"IDT Australia Ltd - Five-Year Contract With Initial a$3.2M Work Expected to Complete by FY2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2526220138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526220138?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:40","pubTimestamp":1744155641,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM28L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7096","IDT.AU"],"gpt_icon":0},{"id":"2526016822","title":"IDT Australia - Secures Manufacturing Contract With Nacuity Pharmaceuticals for Rp Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526016822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526016822?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:40","pubTimestamp":1744155641,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM28L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IDT.AU","BK7096","BK7501"],"gpt_icon":0},{"id":"2526224728","title":"Australia's Accc - Woolworths' Acquisition of Beak & Johnston Not Opposed","url":"https://stock-news.laohu8.com/highlight/detail?id=2526224728","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526224728?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:38","pubTimestamp":1744155507,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM244:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","WOW.AU","BK7040","BK7501"],"gpt_icon":0},{"id":"2526224088","title":"Australia's Accc - Unlikely Acquisition Would Have Substantial Anti-Competitive Effect","url":"https://stock-news.laohu8.com/highlight/detail?id=2526224088","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526224088?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:38","pubTimestamp":1744155507,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM244:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7040","BK7511","WOW.AU"],"gpt_icon":0},{"id":"2526822471","title":"Ansell Loses Bull Despite Tariff Mitigation Plans -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526822471","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526822471?lang=en_us&edition=fundamental","pubTime":"2025-04-09 07:36","pubTimestamp":1744155360,"startTime":"0","endTime":"0","summary":"2336 GMT - Ansell loses its bull at Macquarie despite the protective-glove manufacturer's confidence that it can offset the impact of U.S. tariffs through price rises. Telling clients that they prefer to be safe than sorry, Macquarie analysts lower their recommendation to neutral from outperform on skepticism that Ansell can fully offset the impact in this way. They think that higher prices could offset 75% of the tariff hit, warning in a note that macroeconomic headwinds for Ansell's industrial customers may be a bigger problem for earnings. Macquarie cuts its target price 23% to A$31.05. Shares are at A$29.39 ahead of the open. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANN.AU","BK7501","BK7126"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":106,"code":"91000000","status":"200"}]}}